|
Name |
Verticillin A
|
| Molecular Formula | C30H28N6O6S4 | |
| IUPAC Name* |
(1S,2S,11R,14S)-2-hydroxy-3-[(1S,2S,3S,11R,14S)-2-hydroxy-14,18-dimethyl-13,17-dioxo-15,16-dithia-10,12,18-triazapentacyclo[12.2.2.01,12.03,11.04,9]octadeca-4,6,8-trien-3-yl]-14,18-dimethyl-15,16-dithia-10,12,18-triazapentacyclo[12.2.2.01,12.03,11.04,9]octadeca-4,6,8-triene-13,17-dione
|
|
| SMILES |
C[C@]12C(=O)N3[C@@H]4[C@]([C@@H]([C@@]3(C(=O)N1C)SS2)O)(C5=CC=CC=C5N4)C67[C@@H]([C@]89C(=O)N([C@](C(=O)N8[C@H]6NC1=CC=CC=C71)(SS9)C)C)O
|
|
| InChI |
InChI=1S/C30H28N6O6S4/c1-25-21(39)35-19-27(13-9-5-7-11-15(13)31-19,17(37)29(35,45-43-25)23(41)33(25)3)28-14-10-6-8-12-16(14)32-20(28)36-22(40)26(2)34(4)24(42)30(36,18(28)38)46-44-26/h5-12,17-20,31-32,37-38H,1-4H3/t17-,18-,19+,20+,25-,26-,27+,28?,29-,30-/m0/s1
|
|
| InChIKey |
IMGTYEJTVRXGLW-LTEJGUQOSA-N
|
|
| Synonyms |
Verticillin A; 32164-16-2
|
|
| CAS | NA | |
| PubChem CID | 101647516 | |
| ChEMBL ID | NA |
Chemical Classification: |
|
|
|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
|---|---|---|---|---|---|---|---|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
| Molecular Weight: | 696.8 | ALogp: | 1.0 |
| HBD: | 4 | HBA: | 12 |
| Rotatable Bonds: | 1 | Lipinski's rule of five: | Rejected |
| Polar Surface Area: | 247.0 | Aromatic Rings: | 12 |
| Heavy Atoms: | 46 | QED Weighted: | 0.323 |
| Caco-2 Permeability: | -5.702 | MDCK Permeability: | 0.00001280 |
| Pgp-inhibitor: | 0.953 | Pgp-substrate: | 0.571 |
| Human Intestinal Absorption (HIA): | 0.614 | 20% Bioavailability (F20%): | 0.975 |
| 30% Bioavailability (F30%): | 0.995 |
| Blood-Brain-Barrier Penetration (BBB): | 0.159 | Plasma Protein Binding (PPB): | 77.82% |
| Volume Distribution (VD): | 1.396 | Fu: | 13.48% |
| CYP1A2-inhibitor: | 0.016 | CYP1A2-substrate: | 0.106 |
| CYP2C19-inhibitor: | 0.957 | CYP2C19-substrate: | 0.944 |
| CYP2C9-inhibitor: | 0.977 | CYP2C9-substrate: | 0.119 |
| CYP2D6-inhibitor: | 0.349 | CYP2D6-substrate: | 0.068 |
| CYP3A4-inhibitor: | 0.946 | CYP3A4-substrate: | 0.988 |
| Clearance (CL): | 7.521 | Half-life (T1/2): | 0.015 |
| hERG Blockers: | 0 | Human Hepatotoxicity (H-HT): | 0.132 |
| Drug-inuced Liver Injury (DILI): | 0.988 | AMES Toxicity: | 0.007 |
| Rat Oral Acute Toxicity: | 0.936 | Maximum Recommended Daily Dose: | 0.842 |
| Skin Sensitization: | 0.912 | Carcinogencity: | 0.604 |
| Eye Corrosion: | 0.003 | Eye Irritation: | 0.006 |
| Respiratory Toxicity: | 0.316 |
| Similar NPs | Similar Drugs | ||||||
|---|---|---|---|---|---|---|---|
| NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
| ENC003588 | ![]() |
0.926 | D0SP3D | ![]() |
0.237 | ||
| ENC003382 | ![]() |
0.891 | D01TSI | ![]() |
0.236 | ||
| ENC003381 | ![]() |
0.878 | D0E0RY | ![]() |
0.234 | ||
| ENC004849 | ![]() |
0.784 | D0W7RJ | ![]() |
0.233 | ||
| ENC003490 | ![]() |
0.773 | D0V3ZA | ![]() |
0.230 | ||
| ENC001500 | ![]() |
0.658 | D09NNH | ![]() |
0.225 | ||
| ENC004848 | ![]() |
0.586 | D0V9WF | ![]() |
0.219 | ||
| ENC002358 | ![]() |
0.445 | D0J5YC | ![]() |
0.215 | ||
| ENC003992 | ![]() |
0.442 | D0R5OS | ![]() |
0.208 | ||
| ENC003530 | ![]() |
0.428 | D02TJS | ![]() |
0.206 | ||